Release of Restricted Securities from ASX Mandatory Escrow

2 December 2025

LTR Pharma Limited (ASX:LTP) ("LTR Pharma" or "the **Company)** advises pursuant to ASX Listing Rule 3.10A that the following securities will be released from ASX mandatory escrow.

Type of Security	Number of Securities	Restriction Period
Fully paid ordinary shares	69,014,764	Held in escrow until 11 December 2025, being 24 months from the date of quotation
Options exercisable at $0.26 on or before 11 December 2026	2,792,344	Held in escrow until 11 December 2025, being 24 months from the date of quotation
Options exercisable at $0.22 on or before 11 December 2028	2,000,000	Held in escrow until 11 December 2025, being 24 months from the date of quotation

As per the Market Announcement - Admission and Quotation dated 7 December 2023, the abovementioned fully paid ordinary shares and options will be released from ASX mandatory escrow on the 11 December 2025, being 24 months from the date of quotation.

Pursuant to ASX Listing Rule, 2.8.5, the Company will apply for quotation of the 69,014,764 fully paid ordinary shares released from ASX mandatory escrow within 5 business days after the end of the escrow period.

Executive Chairman Lee Rodne has a relevant interest in 52,673,534 of the shares being released from ASX mandatory escrow. As the Company's largest shareholder, Mr Rodne's interests remain strongly aligned with those of all LTR Pharma shareholders.

- ENDS –

This announcement has been approved by the Board of Directors.

About LTR Pharma

LTR Pharma is a commercial-stage pharmaceutical company delivering innovative therapies for significant unmet medical needs through its proprietary intranasal drug delivery platform. The Company has successfully commercialised its rapid-acting treatment technology in Australia and is expanding access whilst advancing regulatory pathways in the US and other key markets.

LTR's lead products, SPONTAN® and ROXUS®, are fast-acting intranasal sprays for the treatment of erectile dysfunction, enabling onset of action in 10 minutes or less. Building on this proven technology, the Company is now advancing OROFLOW®, a novel intranasal spray under development for the treatment of Oesophageal Motility Disorders (OMD) – a debilitating group of conditions affecting swallowing function.

Through strategic partnerships, LTR Pharma is expanding its pipeline and global footprint to deliver differentiated, patient-centric treatments that enhance quality of life.

For further information please contact:

Media enquiries
Haley Chartres
haley@hck.digital

Investor enquiries
Peter McLennan
investors@ltrpharma.com